Physician profile
Jeffrey Larson
NPI 1013166990
$6,389.10
in general payments reported to CMS, 2019-2025
38 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $109 · 2021: $1,419 · 2022: $1,774 · 2023: $560 · 2024: $513 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522 · Travel and Lodging: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.70 |
| Travel and Lodging | $385.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,561.40 | 2021-2025 | Urolift |
| Medtronic USA, INC. | $660.04 | 2019 | |
| Medtronic, INC. | $486.60 | 2021-2025 | |
| Astellas Pharma US INC | $336.22 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $261.82 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $232.86 | 2019-2024 | Advance Xp, Rezum Generator, Xpeeda Dsl Fiber |
| Abbvie INC. | $172.15 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $163.38 | 2019-2024 | Keytruda |
| Sumitomo Pharma America, INC. | $155.19 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $132.40 | 2019-2024 | |
| Antares Pharma, INC. | $115.17 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $115.01 | 2021-2024 | |
| Neotract INC. | $99.63 | 2019-2020 | |
| Convatec INC. | $82.37 | 2019-2024 | |
| Innovation Technologies INC | $75.58 | 2024-2025 | Irrisept |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $69.92 | 2021-2022 | |
| Intuitive Surgical, INC. | $60.83 | 2021-2023 | Da Vinci Surgical System |
| Ferring Pharmaceuticals INC. | $50.23 | 2025 | Adstiladrin |
| Laborie Medical Technologies Corp. | $49.82 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $45.16 | 2024 | Prolaris |
| Novartis Pharmaceuticals Corporation | $43.58 | 2022 | |
| Amgen INC. | $40.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $37.34 | 2021 | |
| Procept Biorobotics Corporation | $33.01 | 2025 | |
| Accord Healthcare, INC. | $32.98 | 2023 | |
| Endo Pharmaceuticals INC. | $29.33 | 2019-2022 | |
| Hollister Incorporated | $29.29 | 2021-2023 | Infyna Chic, Vapro Pocket, Vapro |
| Blue Earth Diagnostics | $28.96 | 2023 | |
| Myovant Sciences INC. | $24.57 | 2021 | |
| Travere Therapeutics, INC. | $22.60 | 2020 | |
| Clarus Therapeutics INC. | $22.23 | 2021 | |
| Halozyme INC | $20.49 | 2023 | |
| Progenics Pharmaceuticals, INC. | $19.96 | 2023 | Pylarify |
| 180 Medical, INC. | $19.36 | 2019 | |
| Endo USA, INC. | $17.91 | 2025 | Xiaflex, Aveed |
| Cook Medical LLC | $17.61 | 2019 | |
| Ambu INC. | $12.83 | 2021 | |
| Allergan, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.